| Project/Area Number |
15H04703
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Pathological medical chemistry
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
KUBOTA YUJI 東京大学, 医科学研究所, 助教 (70614973)
NAKAMURA TAKANORI 東京大学, 医科学研究所, 助教 (30707576)
NISHIZUMI NORIKO 東京大学, 医科学研究所, 技術専門職員 (30396882)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2017: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2016: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2015: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
|
|---|
| Keywords | エピゲノム制御 / がん / ERK / MAPキナーゼ / CtBP / 転写制御 / シグナル伝達 / 遺伝子 / 癌 / 発現制御 / リン酸化 / 生体分子 / EMT |
|---|
| Outline of Final Research Achievements |
The ERK pathway not only upregulates growth-promoting genes, but also downregulates anti-proliferative genes. In particular, ERK signaling contributes to repression of the E-cadherin gene during EMT. The CtBP co-repressor is also involved in gene silencing of E-cadherin. However, the functional relationship between ERK signaling and CtBP is unknown. In this study, we identified an ERK substrate MCRIP1, which bridges ERK signaling and CtBP-mediated gene silencing. CtBP is recruited to promoter elements of target genes by interacting with the transcriptional repressor ZEB1. We found that MCRIP1 binds to CtBP, thereby inhibiting CtBP-ZEB1 interaction. When phosphorylated by ERK, MCRIP1 dissociates from CtBP, allowing CtBP to interact with ZEB1. In this manner, CtBP is recruited to, and silences, the E-cadherin promoter by inducing chromatin modifications. Our findings reveal a mechanism underlying ERK-induced epigenetic gene silencing of tumor suppressors and its dysregulation in cancer.
|
